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Comments on: Laboratory tests
for  the management of major
bleeding complications and
emergency surgery in patients
on long-term treatment with
direct oral anticoagulants: Pro-
posals  of the Working Group
on Perioperative Haemostasis
(GIHP)
Tests  de  laboratoire  dans  la  prise  en  charge  des
saignements majeurs  et  la  chirurgie  urgente  chez  les
patients  sous  traitement  anticoagulant  oral  direct  au
long cours  :  propositions  du  Groupement
d’intervention  en  hémostase  périopératoire  (GIHP)
Keywords:  Direct  oral  anticoagulants;  Surgery;  Laboratory
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Mots  clés  :  Anticoagulants  oraux  directs  ; Chirurgie  ;  Test
de  laboratoire
We  read  with  interest  the  proposal  of  the  Working  Group
on  Perioperative  Haemostasis  (GIHP),  published  in  a  recent
issue  of  Archives  of  Cardiovascular  Diseases  by  Pernod  et  al.
[1].  One  of  the  aims  of  the  proposal  was  to  provide  infor-
mation  on  the  use  of  coagulation  tests  carried  out  at  the
time  when  emergency  surgery  is  required  in  patients  treated
with  the  direct  oral  anticoagulants  (DOACs)  dabigatran  or
rivaroxaban.  The  authors  pointed  out  correctly  that  the
data  available  at  the  moment  are  scanty  and  do  not  allow
ﬁrm  recommendations.  Nevertheless,  speciﬁc  plasma  con-
centrations  of  dabigatran  or  rivaroxaban  below  which  urgent
surgery  can  be  carried  out  have  been  reported  [1].  Further-
more,  the  authors  propose  that  when  plasma  concentrations
are  not  available,  one  can  rely  on  the  results  of  the  two  most
commonly  available  coagulation  tests,  prothrombin  (PT)  and
activated  partial  thromboplastin  time  (aPTT)  [1].  Speciﬁ-
cally,  the  authors  mentioned  that  <  30  ng/mL  for  either  drug
is  safe  and  surgery  can  be  carried  out  without  signiﬁcant
bleeding  risk.  Likewise,  they  proposed  that  a  PT  or  aPTT
ratio  <  1.2  can  be  taken  as  a  threshold  limit  to  perform
surgery  [1].  We  understand  and  appreciate  how  it  is  impor-
tant  to  provide  information  at  the  time  when  these  drugs  will
be  used  and  patients  may  need  to  be  subjected  to  emergency
d
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1875-2136/© 2014 Elsevier Masson SAS. All rights reserved.urgery.  Nevertheless,  we  wish  to  comment  on  the  value  of
uch  proposals.
rug  concentrations
s  stated  by  the  authors,  the  proposed  threshold  values
or  dabigatran  or  rivaroxaban  do  not  stem  from  clinical
bservations  and  are  based  largely  on  the  drug’s  pharma-
okinetics  [1].  According  to  the  European  Medicine  Agency
nnexes  Summary  of  Product  Characteristics  for  both  drugs
2,3],  the  steady-state  concentration  of  plasma  dabigatran
xpected  on  the  basis  of  the  interindividual  variability  spans
rom  117  ng/mL  to  275  ng/mL  at  the  peak  level,  and  from
1  ng/mL  to  143  ng/mL  at  the  trough  level,  both  taken  as  the
5th  to  75th  percentile  range  [2].  Likewise,  the  plasma  con-
entrations  of  rivaroxaban  vary  from  22  ng/mL  to  535  ng/mL
t  the  peak,  and  from  6  ng/mL  to  239  ng/mL  at  the  trough
evel,  both  taken  as  the  90%  prediction  interval  [3].  It  is
nclear  where  these  values  come  from  and  how  they  have
een  determined.  However,  one  may  assume  that  they  come
rom  the  clinical  trials  and  that  the  method  of  determi-
ation  was  mass  spectrometry.  Also,  it  was  not  speciﬁed
hether  these  values  were  or  not  associated  with  clinical
leeding.
All  in  all,  the  above  observations  point  to  the  fact  that
hreshold  values  for  safe  emergency  surgery  are  presently
nknown.  If  this  is  the  case,  we  wonder  whether  provid-
ng  threshold  values  (although  with  some  caveats)  as  the
uthors  did  in  their  proposal  is  not  detrimental  to  patient
anagement  as  these  values  may  give  a  false  reassurance
o  those  who  are  not  particularly  familiar  with  the  effect  of
OACs.
T  and  aPTT
he  threshold  presurgical  prolongations  for  PT  and  aPTT
rovided  by  the  working  group  (i.e.  a  ratio  <  1.2)  are
ased  largely  on  considerations  stemming  from  the  rela-
ive  half-life  of  the  circulating  drugs  and  on  the  relative
esponsiveness  of  aPTT  or  PT  reagents  stemming  from  results
btained  by  spiking  in-vitro  normal  plasmas  with  known  and
ncreasing  concentrations  of  either  drug  [4—7].  It  should
e  mentioned  that  the  situation  might  be  different  when
ne  investigates  plasmas  from  patients  treated  with  either
rug.  Such  observations  are  now  available.  Hawes  et  al.
8]  have  in  fact  investigated  plasmas  from  patients  treated
ith  dabigatran.  According  to  their  results,  the  PT  and
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our  working  group,  we  decided  that  experts  must  develop
an  opinion  precisely  for  such  cases  where  there  is  no
clear  guidance.  Moreover,  we  addressed  the  proposals  for46  
PTT  are  often  normal  in  spite  of  therapeutic  dabigatran
lasma  levels.  Furthermore,  there  was  a  relatively  large
etween—reagent  variability  in  the  response  to  dabigatran.
s  an  example,  when  the  aPTT  was  run  with  a  particu-
ar  reagent,  35%  of  the  aPTT  ratios  were  in  the  normal
ange  when  the  dabigatran  plasma  concentration  was  up
o  100  ng/mL.  Rodgers  et  al.  [9]  investigated  patients  on
ivaroxaban  and  found  that  the  recombinant  thromboplas-
in  they  used  was  adequately  responsive  to  rivaroxaban.  On
he  contrary,  van  Veen  et  al.  [10],  while  investigating  their
atients  on  rivaroxaban  with  another  recombinant  throm-
oplastin,  found  that  it  was  unresponsive  to  rivaroxaban.
hese  results  clearly  demonstrate  that  providing  presurgi-
al  cut-off  values  without  taking  into  proper  consideration
he  responsiveness  of  the  aPTT  or  PT  tests  to  dabigatran
r  rivaroxaban  may  create  a  dangerous  situation  for  patient
anagement.
isclosure  of  interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
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ear  editor,
We  appreciate  the  pertinent  comment  from  Dr  Tripodi
1]  on  the  proposals  of  the  Working  Group  on  Perioperative
aemostasis,  regarding  management  of  major  bleeding  and
mergency  surgery  in  patients  on  long-term  treatment  with
irect  anticoagulants  [2]. Several  clariﬁcations  need  to  be
ade.
As  highlighted  by  Dr  Tripodi,  recommendations  can-
ot  be  established  because  of  the  lack  of  data  in  the
mergency  situation.  Therefore,  several  mundane  propo-
als  can  be  put  forward,  such  as:  ‘ideally,  surgery  must  be
elayed’;  but  how  many  times,  and  for  what  purpose?  InDOIs of original articles:
ttp://dx.doi.org/10.1016/j.acvd.2014.04.003,
ttp://dx.doi.org/10.1016/j.acvd.2013.04.009.
